Latest Payments News

Equity Story Group Ltd (ASX:EQS) reports a robust December quarter marked by significant growth in funds under management, membership fees, and capital markets revenue, alongside strategic cost reductions positioning the company for sustained 2025 growth.

EVE Health Group has completed the sale of its Robyndale tea tree property and relaunched its postbiotic concentrate range, signaling a strategic shift towards innovation and growth in the Australian market.

Green Critical Minerals has made significant strides in commercialising its Very High-Density (VHD) Graphite technology, achieving exceptional pilot plant results and positioning itself at the forefront of clean energy and electronics markets.

Magnum Mining and Exploration Limited moves forward with acquiring two promising rare earth element projects in Brazil while progressing negotiations on a green pig iron venture in Saudi Arabia.

DXN Limited reported a robust 58.1% revenue increase to $4.8 million in Q2 FY25, underpinned by strategic capital raising and new product innovation targeting AI infrastructure. The company is advancing key mining and telecom projects while streamlining operations to support its ambitious $16 million revenue guidance for FY25.

NSX Limited reports a $1.6 million cash injection from ISXFEU, completes the ClearPay joint venture sale, and reduces operational costs in its 2Q25 activities report, while facing delays in share issuance approval.

Latitude Group Holdings Limited has announced a quarterly distribution of AUD 2.2291 per Capital Note, payable in late April 2025, continuing its steady income stream for investors.

Icon Energy Limited reported a $455K cash balance and issued 100 million shares this quarter to sustain operations amid ongoing uncertainty over the ATP 855 permit renewal.

Carbine Resources reports steady progress on its Muchea West silica sand mining licence application, engaging environmental consultants to support upcoming approvals. The company also continues exploration efforts at its Down South project.

Bluechiip Limited advances its strategic repositioning with a new licensing agreement valued up to USD 750,000 alongside ongoing efforts to lift its trading suspension and grow sales.

Zelira Therapeutics has secured a fourth funding tranche of US$681,000, advancing its HOPE® Autism Spectrum Disorder FDA trial process and bringing total funding to US$3.25 million. The company is progressing clinical validation and product development, including the transformation of Zenivol® into a capsule formulation.

Traka Resources reports steady progress in its December 2024 quarter, focusing on exploration at Gorge Creek and Cranbrook while withdrawing from Mozambique projects to sharpen its strategic focus.